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1. Introduction 
Brain metastases are a frequent complication in patients with lung cancer and a significant 
cause of morbidity and mortality. Brain metastases are found in about 10-25% of patients at 
the time of diagnosis, and approximately 40-50% of all patients with lung cancer develop 
brain metastases during the course of their disease, with greater frequency at autopsy 
(approximately 50%) than predicted from the presence of symptoms (1). The incidence of 
brain metastasis is increasing mainly due to longer patient survivals resulting from newer 
treatment modalities. Most patients with lung cancer metastatic to the brain have multiple 
lesions (2). Brain metastases are usually associated with poor outcomes and shortened 
survival of 3 to 6 months. Standard treatment options include symptomatic therapy with 
corticosteroids and whole-brain radiotherapy (WBRT) (3), and more aggressive approaches 
such as surgery or radiosurgery are indicated in a subset of patients (4,5). Surgical resection 
of accessible brain metastases combined with postoperative WBRT is the management of 
choice for a single metastasis (6). However, radiosurgery for brain metastases produces high 
rates of tumor control similar to the rates obtained by excisional surgery (7). Patients with 
multiple brain metastases are commonly treated with WBRT for the palliation of symptoms 
(8). The role of radiosurgery for multiple brain metastases is less clear, but it can be effective 
(9). The poor outcomes and relapses following WBRT alone indicate a need for new 
therapeutic options. Generally, poor prognosis occurs not from cerebral problems, but from 
extracranial metastases, and death is caused by systemic disease combined with the 
neurological condition (10). However, treatment with systemic chemotherapy is 
controversial because chemotherapeutic agents may not cross the blood-brain-barrier (BBB) 
and therefore are less effective against central nervous system (CNS) disease than against 
extracranial, systemic disease. However, the BBB is partially disrupted in brain metastases 
(11) and similar concentrations of chemotherapeutic agents are found in intracerebral and 
extracerebral tumors (5). Brain metastases resulting from both non-small-cell (NSCLC) and 
small-cell lung cancer (SCLC) are susceptible to systemic chemotherapy, and cerebral 
response rates up to 50% were observed even in second-line treatment of NSCLC and SCLC 
(1,10,11). Still, medical therapies for brain metastases are neither well-studied nor 
established. Here, I analyze the impact of medical treatment on survival by reviewing recent 
articles and provide recommendations for the management of patients with brain 
metastases from lung cancer. 
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2. Non-small cell lung cancer (NSCLC) 
NSCLC accounts for approximately 75% of lung cancer cases, with the majority of patients 
having inoperable, locally advanced or metastatic disease at the time of diagnosis, reflected 
in the low 5-year survival rate for all stages (currently 13%) (12). Despite two decades of 
cisplatin-based chemotherapy of advanced NSCLC, the survival benefit remains modest 
(13). New chemotherapy combinations have minimal impact on survival compared with 
older regimens, with overall response rates of approximately 30%, median survival benefits 
of 8–9 months, and 1-year survival rates of approximately 30% (14). New therapies are 
required that are effective against locally advanced or metastatic NSCLC. 
2.1 Front-line chemotherapy (Table 1) 
Many chemotherapeutic regimens have been tested in phase II or III trials for the treatment 
of brain metastases arising from NSCLC. There are 8 larger reports (15-22) with more than 
10 patients, published from 1994 to 2008 in English, on front-line chemotherapy of brain 
metastases from NSCLC. In patients with NSCLC, 17-50% of patients with previously 
untreated brain metastases responded to a combination of cisplatin plus fotemustine; 
carboplatin plus etoposide; cisplatin plus teniposide; cisplatin plus etoposide; cisplatin plus 
ifosfamide, CPT-11; cisplatin plus vinorelbine; carboplatin plus vinorelbine, gemcitabine; 
cisplatin plus paclitaxel. Systemic disease activity correlates well with activity against brain 
metastases, but overall survival (OS) is still 4-12 months. 
 
Author Regimen No. of 
patients
Study 
design
Response 
rate (%)
Disease 
stabilization 
(%) 
mPFS 
(Month) 
OS 
(Month) 
Cotto C CDDP,Fotemustine 31 Phase II 23 51.6 5 4 
Malacarne P CBDCA,VP16 18 Phase II 17 39 n.d. 7.5 
Minotti V CDDP,Teniposide 23 Phase II 35 65 7 5 
Franciosi  V CDDP,VP-16 43 Phase II 30 65 4 8 
Fujita A CDDP,IFOS,CPT-11 28 Phase 
I/II 
50 96 4.6 12 
Robinet G CDDP,VNR 76 Phase III 27 n.d. 3.2 6 
Bernardo G CBDCA,VNR,GEM 22 Phase II 45 85 6.2 8.2 
Cortes J CDDP,Paclitaxel 26 Phase II 38 69 3.2 5.3 
Table 1.CBDCA,carboplatin; CDDP, cisplatin; CPT-11, irinotecan; GEM, gemcitabine; IFOS, 
ifosfamide; mOS, median overall survival; mPFS, median progression free survival; n.d., not 
determined; VNR, vinorelbine;  VP16, etoposide. Modified from: Yamanaka R. Oncol Rep 
2009;22:1269-1276 with permission from Spandidos Publications 
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2.2 Second-line chemotherapy 
2.2.1 Epidermal growth factor receptor tyrosine kinase Inhibitor  
The epidermal growth factor receptor (EGFR) is expressed in a variety of tumors, including 
NSCLC (23), and elevated EGFR expression is associated with a poor prognosis in lung 
cancer patients (24). Several EGFR-targeted agents have been developed, including gefitinib 
(ZD1839; Iressa) and erlotinib (OSI-774; Tarceva), an orally active anilinoquinazoline 
compound that inhibits EGFR tyrosine kinase activity (25). In two large, well-designed 
phase II clinical trials, refractory patients with NSCLC experienced overall response rates of 
11.8–18.4%, median survival benefits of 6.5–7.6 months, and 1-year survival rates of 29–35% 
(26,27), with encouraging response rates in select patients (women, non-smokers, patients 
with adenocarcinoma, and specific EGFR mutations in the kinase domain) (28-33).  
Although targeting EGFR-associated tyrosine kinase with gefitinib and erlotinib results in 
durable responses in some patients, the activity of these drugs against brain metastases has 
been poorly documented so far.  
Gefitinib  (Table 2) 
Phase II studies of gefitinib on brain metastases from NSCLC indicated objective responses 
occur in 33% of patients (Asia) (34,35) or 9.7% of patients (Europe) (36). In comparison, 
WBRT with 30 to 40 Gy for brain metastases from NSCLC results in objective responses in 
38% to 45% of patients (37,38). Gefitinib is well tolerated, mostly with grade 1/2 skin rashes. 
The severity of skin toxicity was tightly associated with tumor response and patient survival 
(34). Gefitinib was most effective at treating brain metastases in patients with EGFR 
mutations in the tyrosine kinase domain (deletion mutation in two patients and a point 
mutation in one patient) in one study (39). However, this analysis was performed using 
tissue samples from primary lung cancer and not from metastatic brain lesions. Yokouchi et 
al (40). reported that some patients who experienced disease progression after responding to 
gefitinib were sensitive to gefitinib re-administration after temporary cessation of gefitinib 
and other treatments. Patients may still be expected to have prolonged survival if they once 
responded to gefitinib and then underwent various subsequent treatments followed by re-
administration of gefitinib. These findings might provide valuable information for the 
management of gefitinib-responders. Although the survival benefit is controversial, gefitinib 
may also be useful for the treatment of carcinomatous meningitis from NSCLC to improve 
neurological dysfunction (41,42,43). Thus, gefitinib has therapeutic potential for palliative 
therapy in patients with brain metastases. 
 
Author No. of 
patients
Study 
design 
Previous 
WBRT/Chemo 
(%) 
Response 
rate (%)
Disease 
stabilization 
(%) 
mPFS 
(Month) 
OS 
(Month) 
Ceresoli GL 41 phase II 43.9/90.2 9.7 26.8 3 5 
Chiu CH 76 phase II n.d./84.2 33.3 63.2 5 9.9 
Wu C 40 phase II 65/100 32 77 9 15 
Table 2. Chemo, chemotherapy; mOS, median overall survival; mPFS, median progression 
free survival; n.d., not determined; WBRT, whole brain radiotherapy. Modified from: 
Yamanaka R. Oncol Rep 2009;22:1269-1276 with permission from Spandidos Publications. 
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Erlotinib  
Erlotinib treatment of brain metastases from NSCLC has been reported in 20 cases (44-55). 
These were histologically confirmed as adenocarcinoma in the primary site. The main 
adverse events were Grade 1 skin rashes. Some patients had responses longer than 6 
months.  Erlotinib responses are higher in patients with a somatic mutation in EGFR or a 
point mutation in the activation loop of the kinase domain (56,57). Thirteen patients showed 
a response to erlotinib after gefitinib failure. Although gefitinib failure may result from 
cross-resistance to other EGFR tyrosine kinase inhibitors (EGFR-TKI), these cases suggest 
that re-challenging patients with EGFR-TKI may be beneficial. At the recommended dosage, 
erlotinib showed higher blood concentrations than gefitinib, and may also have higher in 
cerebral spinal fluid. In addition, two patients with intracranial lesions responded to 
erlotinib treatment although extra-cranial lesion progressed. In the Rupport case (51), a 
secondary T790M mutation associated with resistance to EGFR-TKI was found in the liver 
biopsy. Erlotinib was reintroduced and produced quick neurological improvement, even 
though the extra-cranial disease remained resistant to erlotinib. These cases also highlight 
the oligoclonal nature of NSCLC and its differential sensitivity to EGFR-TKIs, in that extra-
cranial disease was resistant to erlotinib both initially and on re-challenge. Persistent 
cerebral TKI sensitivity should be considered in patients presenting with a CNS relapse after 
stopping EGFR-TKI, even with a T790M resistant mutation in non-cerebral metastases. In 
addition, erlotinib should be considered for treatment of intra-cranial disease.  
2.2.2 Temozolomide (Table 3) 
Temozolomide is an orally administered prodrug that is converted spontaneously to the 
active alkylating agent, monomethyl triazenoimidazole carboxamide, at physiologic pH, 
crosses the BBB, and has antitumor activity against malignant glioma, melanoma, NSCLC, 
and carcinoma of the ovary and colon (58). CNS concentrations reach approximately 30–40% 
of plasma levels, achieving therapeutic concentrations in the brain (59), and clearance of 
temozolomide is unaffected by co-administration with anticonvulsants, antiemetics, or 
dexamethasone (58,59). The dose-limiting toxicity is non-cumulative myelosuppression that 
rarely requires treatment delays or dose reductions. In patients with newly-diagnosed brain 
metastases or with progression after radiotherapy, temozolomide produces objective 
response rates between 5 and 10% (60-62) and is well tolerated.  
 
Author Regimen No. of 
patients
Study  
design 
Previous 
WBRT/Chemo 
(%) 
Response
 rate (%)
Disease 
stabilization 
(%) 
mPFS 
(Month) 
OS 
(Month
) 
Giorgio TMZ 30 phase II 100/100 10 20 3.6 6 
Kouroussis C TMZ 12 phase II n.d./100 8.3 25 n.d. n.d. 
Abrey LE TMZ 22 phase II 100/n.d. 9 45 n.d. n.d. 
Christodoulou  
C 
TMZ 12 phase II 100/n.d. 8 n.d. n.d. n.d. 
Table 3. TMZ,temozolomide; Chemo, chemotherapy; mOS, median overall survival; mPFS, 
median progression free survival; n.d., not determined; WBRT, whole brain radiotherapy. 
Modified from: Yamanaka R. Oncol Rep 2009;22:1269-1276 with permission from Spandidos 
Publications 
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2.2.3 Temozolomide plus other chemotherapeutic agents  
Preclinical experiments and early clinical studies in other malignancies indicate that 
temozolomide may have additive or synergistic effects when used with other 
chemotherapeutic agents (64,65). In addition, its minimal toxicity allows for the combination 
of temozolomide with gemcitabine, gemcitabine/cisplatin, or gemcitabine/vinorelbine in 
NSCLC patients to produce dramatic cerebral responses (66,67). The combination of 
temozolomide with other chemotherapeutic agents represents a promising strategy for 
treating brain metastases. 
2.3 Chemotherapy plus whole-brain irradiation (Table 4) 
Combining chemotherapy with brain radiotherapy is attractive because chemotherapy is 
active against both primary tumors and brain metastases, and because chemotherapy may 
act as a radiosensitizer. Two studies have compared randomized chemotherapy alone with 
chemotherapy/WBRT. Quantin et al. (68) reported a phase II study of radiotherapy plus 
vinorelbine, ifosfamide, and cisplatin chemotherapy in patients with brain metastases of 
NSCLC. The response rate was 56% and median survival was 7.6 months. The same author 
also reported a phase II study with concomitant brain radiotherapy and high-dose 
ifosfamide in brain relapses (69). Median survival was 13 months. Myelosuppression was 
the main toxic effect, but remained manageable and no toxic deaths occurred. The high 
response rate for brain lesions and improvement in neurological symptoms deserves further 
exploration. 
 
Author Chemotherapy 
Regimen 
No. of 
patients
Study 
design 
Previous 
WBRT/Chemo 
(%) 
Response 
rate (%)
Disease 
stabilization
(%) 
mPFS 
(Month) 
OS 
(Month) 
Quantin CDDP,VNR, 
IFOS 
23 phase II 0/0 56 65 n.d. 7.6 
Quantin high-dose  
IFOS 
16 phase II n.d./n.d. 25 n.d. n.d. 13 
Ma S Gefitinib 25 phase II 0/0 81 95.2 10 13 
Addeo R TMZ 15 phase II 44/74 6.5 60 6 8.8 
Cortot CDDP,TMZ 50 phase II 6/n.d. 12 54 2.3 5 
Robinet CDDP,VNR 85 phase III 0/0 28 n.d. 2.7 5.2 
Table 4. CDDP, cisplatin; Chemo, chemotherapy; IFOS, ifosfamide; mOS, median overall 
survival; mPFS, median progression free survival; n.d., not determined; 
TMZ,temozolomide; VNR,vinorelbine; WBRT, whole brain radiotherapy. Modified from: 
Yamanaka R. Oncol Rep 2009;22:1269-1276 with permission from Spandidos Publications 
Ma et al. (70) found that treatment with concomitant gefitinib and WBRT was well tolerated, 
with significant improvement of neurological symptoms in a Chinese population with brain 
metastases from NSCLC. Addeo et al. (71) reported response rates of 6.5% using a 
combination of temozolomide and WBRT. Cortot et al. (72) reported response rates of 12% 
with temozolomide, cisplatin, and WBRT. A randomized phase II study evaluated the 
efficacy of concurrent temozolomide and radiotherapy versus radiotherapy alone in 58 
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patients with previously untreated brain metastases from different solid tumors (31 patients 
had NSCLC) (73). The temozolomide group showed significant improvements in cerebral 
response rate (96% versus 67%), and temozolomide was safe and well-tolerated. However, 
overall survival rates and changes in neurological function were similar in both groups. 
Robinet et al. (74) reported a phase III study comparing the timing of WBRT, either before or 
after chemotherapy, and found a 28% response rate in 85 patients treated with cisplatin and 
vinorelbine in the early WBRT arm. The median survival in this arm was 5.2 months and 
median time to progression (TTP) was 2.1 months. Radiotherapy timing did not change 
survival time. Thus, for NSCLC, WBRT should be added to initial chemotherapy if there is 
no treatment response. 
3. Small Cell Lung Cancer 
The brain is the most common metastatic site in SCLC, and is usually fatal. Approximately 
18-25% of SCLC patients have brain metastases already at diagnosis, and an additional 50% 
will develop CNS involvement during their disease course (75-77). Although WBRT and 
corticosteroids are the treatment of choice, systemic chemotherapy may also have 
therapeutic value. Extracranial disease is almost always present in SCLC, and chemotherapy 
can treat both brain metastases and these other disease sites. Prophylactic cranial irradiation 
(PCI) for patients responsive to induction therapy markedly reduces the risk of CNS relapse 
and significantly improves survival (77,78). Surgical treatment for solitary lesions or 
systemic chemotherapy for multifocal brain metastases that are minimally symptomatic can 
be useful, particularly when these patients also have extracranial metastatic disease. Thus, 
systemic chemotherapy can complement WBRT for treatment of brain metastases in SCLC. 
3.1 Front-line chemotherapy (Table 5) 
There are 4 larger reports (79-82) with more than 10 patients, published from 1989 to 2008 in 
English, on front-line chemotherapy of brain metastases from SCLC. The chemotherapeutic 
regimens, including cyclophosphamide, vincristine, etoposide, doxorubicin and cisplatin, 
produced response rates of 27-82% Thus, chemotherapy followed by radiation therapy may be 
first-line treatment for patients with systemic disease and asymptomatic brain metastases.  
 
Author Regimen No. 
of 
patients
Study 
design 
Response
rate (%) 
Disease 
stabilization 
(%) 
mPFS 
(Month) 
OS 
(Month) 
Lee JS CTX,DX,VCR,VP-
16 
11 Phase II 82 91 6 8.5 
Twelves CJ CTX,VP-16,VCR 25 Retrospecti
ve 
53 n.d. 5.5 8.5 
Kristjansen 
PE 
CDDP,VP-16,VCR 21 Phase II 52 57 4.5 3.7 
Seute T CTX,DX,VP-16 22 Phase II 27 50 n.d. n.d. 
Table 5. CTX, cyclophosphamide; DX, doxorubicin; mOS, median overall survival; mPFS, 
median progression free survival; n.d., not determined; VCR, vincristine; VP16, etoposide; 
Modified from: Yamanaka R. Oncol Rep 2009;22:1269-1276 with permission from Spandidos 
Publications.  
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3.2 Second-line chemotherapy (Table 6) 
SCLC relapse may also require systemic chemotherapy, which showed efficacy in 7 small 
phase II studies (83-89) with chemotherapy as salvage treatment after failing systemic 
chemotherapy and WBRT. Response rates are generally lower and survival is decreased in 
patients who receive chemotherapy for brain metastases after failure following 
radiotherapy. Postmus et al. (83) reported a response rate of 43% in the brain after high-dose 
etoposide. Groen et al. (84) reported a response rate of 40% with carboplatin and Postmus et 
al. (85) reported a response rate of 42% with a single agent, teniposide. The response rates of 
the primary tumor are not given in these reports. Chen et al. (89) reported a high response 
rate of 65% with a combination of carboplatin and irinotecan. In an analysis by Schuette et 
al. (86) and Korfel et al. (88), response rates for brain metastases of 50% and 33%, 
respectively, were achieved with topotecan. In both, the cerebral response rate was superior 
to the response rate of the primary tumor, probably because the intact BBB during the first 
treatment round protected tumor cells of the brain metastases. However, the severe adverse 
events associated with these regimens would be difficult to tolerate for pretreated patients 
who had already received radiation and multiple regimens of myelosuppressive 
chemotherapy. Treatment-related mortality was observed in 7 of 13 patients treated with 
high-dose etoposide (83) and in 8 of 80 patients treated with teniposide (85).   
 
Author Regimen No. of 
patients
Study 
design 
Response 
rate (%)
Disease 
stabilization 
(%) 
mPFS 
(Month) 
OS 
(Month) 
Postmus PE HD-VP16 23 Phase II 43 52 n.d. 8 
Groen H CBDCA 20 Phase II 40 60 2 4 
Postmus PE Teniposide 80 Phase II 33 47.5 4.8 2.9 
Schuette W Topotecan 22 Phase II 50 82 n.d. 6 
Postmus PE Teniposide 60 Phase III 22 43 4.5 3.2 
Korfel A Topotecan 30 Phase II 33 60 3.1 3.6 
Chen G CBDCA, CPT-11 15 Phase II 65 86 n.d. 6 
Table 6. CBDCA,carboplatin; CPT-11, irinotecan; mOS, median overall survival; mPFS, 
median progression free survival; n.d., not determined; HD-VP16, high dose etoposide 
Modified from: Yamanaka R. Oncol Rep 2009;22:1269-1276 with permission from Spandidos 
Publications 
Temozolomide shows low response rates when used alone. Ebert et al. (90) reported a case 
of a patient with SCLC with recurrent brain metastases who was treated with temozolomide 
and oral etoposide. This regimen was well tolerated and resulted in dramatic, durable 
responses. Combining temozolomide with other chemotherapeutic agents represents a 
promising strategy for treating patients with brain metastases from SCLC.  
3.3 Chemotherapy plus whole-brain irradiation 
Postmus et al. (87) reported a phase III study where 120 SCLC patients with brain 
metastases were randomized to receive teniposide with or without WBRT. Combined 
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treatment produced a 57% response rate, and teniposide alone produced a 22% response 
rate. Combined treatment produced a longer TTP, but both regimens produced similar 
clinical responses outside the brain, median survival times (median survival 3.5 and 3.2 
months, respectively) and symptomatic improvement. Further studies are needed to 
compare combinations of WBRT with chemotherapy.  
4. Discussion 
The impairment of physical, cognitive, and affective function that accompanies most brain 
metastases is highly distressing and can be seen as a "loss" of the patient even before death. 
Improved treatment of overt brain metastases may have palliative value and eradication of 
microscopic brain disease may cure patients already cured in other sites. Assumptions about 
BBB penetration and chemotherapy resistance have limited the use of chemotherapy for 
treatment of brain metastases. Small, lipid-soluble molecules can penetrate the normal BBB 
barrier, but large, hydrophilic molecules cannot. Furthermore, high levels of the multidrug 
transporter, P-gp, are expressed in the endothelial cells of brain capillaries. P-gp actively 
prevents drugs from passing through the BBB (91). However, macroscopic metastases, 
relapsed disease, and radiation therapy can disrupt the BBB (92), as shown via magnetic 
resonance imaging (MRI) or computed tomography (CT) of intravenous contrast inside 
intracerebral lesions. In addition, the concentration of chemotherapy drugs, including 
platinum, is similar in intracerebral and extracerebral tumors (5). Cytostatics unable to 
penetrate the BBB produce comparable response rates for cerebral metastases and systemic 
disease, and adding BBB-penetrating drugs such as procarbazine, nitrosoureas, or 
methotrexate to a standard combination regimen did not improve the CNS relapse 
frequency (93,94). The chemosensitivity of the primary tumor is the major determinant of 
the response to systemic treatment for brain metastases (92,95), although asymptomatic 
brain metastases may have lower responses than systemic tumors to systemic chemotherapy 
(82).  
Dexamethasone and enzyme-inducing anti-epileptic drugs (EIAEDs) can induce cytochrome 
p450 3A isoenzymes, including CYP3A4, which metabolizes chemotherapeutic agents 
(96,97) including paclitaxel, irinotecan, vinorelbine, cyclophosphamide, doxorubicin, 
etoposide, ifosfamide, teniposide, erlotinib, and gefitinib. Therefore, co-administration of 
EIAEDs or dexamethasone may increase the metabolism of chemotherapeutic agents, lower 
plasma concentrations, and reduce efficacy.  
Response and survival rates are generally lower after chemotherapy for brain metastases 
following radiotherapy failure (84). Combination regimens also produce side effects that 
would be difficult to tolerate after radiation or multiple regimens of myelosuppressive 
chemotherapy. Oral agents such as gefitinib, erlotinib, and temozolomide were well tolerated 
even in pretreated patients, confirming their favorable adverse event profile. In a molecularly 
selected population with brain metastases, these agents can produce high response rates.  
Brain metastases resulting from both NSCLC and SCLC are susceptible to systemic 
chemotherapy, with cerebral response rates similar to primary tumor responses, even in 
second-line treatment. Clinical conditions such as a chemotherapy-sensitive primary tumor, no 
prior chemotherapy, or the presence of systemic metastases should indicate the use of 
chemotherapy. The brain is rarely the sole site of metastases in lung cancer, and patients 
receiving cranial irradiation alone often die of extra-cranial tumors rather than cerebral 
metastases. Chemotherapy can control other disease sites and is generally better tolerated than 
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WBRT. Chemotherapy should be initiated before WBRT because chemotherapy cannot be 
given for 1 month after WBRT and concomitant WBRT/chemotherapy is more toxic. 
Combinations of these therapeutic modalities for the management of brain metastases  require 
further testing in randomized phase III studies. Because of the short survival times, the late 
effects of cranial irradiation such as dementia may be underestimated because they do not 
usually present until months or years after treatment. Kristensen et al. (98) showed response 
rates of 76% in primary brain metastases from SCLC but only 43% in relapsed metastases, 
similar to other SCLC metastatic sites. Chemotherapy has a clearer therapeutic impact in SCLC 
than NSCLC. Thus, chemotherapy should be incorporated into the management of brain 
metastases as part of a multimodal treatment concept.  
First-line chemotherapy can be performed in patients with asymptomatic or minor 
neurological symptoms or other metastatic sites, as well as for relapses after radiotherapy or 
systemic chemotherapy. The main goal of cytostatic therapy is palliation, with clinical 
improvement and brief, limited duration of high-dose steroid treatments critical to this 
palliation. The inclusion of patients with brain metastases from lung cancer in prospective 
trials of new therapeutic agents or combinations should be pursued. 
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